Current treatment status-Undergoing active treatment-No response Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-No response Posts on Medivizor

Evaluating GVDex chemotherapy for patients with recurrent or persistent Hodgkin’s lymphoma

Posted by on Aug 19, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined if GVDex is as effective and safe as GVDoxil for treating Hodgkin's lymphoma (HL) that has come back or stopped responding to treatment. The authors found that GVDex was as effective as GVDoxil, with fewer side effects. Some background For most patients with HL, primary therapy is highly effective....

Read More

Evaluating nivolumab plus brentuximab vedotin for patients with relapsed or unresponsive primary mediastinal large B-cell lymphoma

Posted by on Aug 17, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated nivolumab (Opdivo) plus brentuximab vedotin (Adcetris) in patients with relapsed or unresponsive primary mediastinal B-cell lymphoma (PMBCL). This study concluded that this combination is promising and was well-tolerated. Some background PMBCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL)....

Read More

Evaluating BCD chemotherapy for patients with peripheral T-cell lymphoma

Posted by on Jul 31, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of BCD chemotherapy (bendamustine, carboplatin, and dexamethasone) for patients with peripheral T-cell lymphoma that has come back or stopped responding to treatment. This study concluded that this treatment was promising, with minimal side effects. Some background Peripheral T-cell...

Read More

Searching for participants with high risk relapsed or unresponsive Hodgkin lymphoma to try a treatment combination.

Posted by on Jul 29, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study will investigate the effects of nivolumab (Opdivo) and brentuximab vedotin (Adcetris) after stem cell transplant in patients with high risk relapsed or refractory Hodgkin lymphoma (RRHL). The main outcome that will be measured is progression-free survival. This trial is recruiting in multiple locations in the United States. The...

Read More

Using alpha-interferon to treat residual chronic myeloid leukemia after transplantation

Posted by on Jul 14, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the effectiveness of interferon-alpha (IntronA) treatment in patients with chronic myeloid leukemia (CML) with residual disease after transplantation. Researchers found that this treatment may be useful in patients with signs of disease after transplant. Some background Chronic myeloid leukemia is a cancer...

Read More

Treatment options for patients with recurrent or non-responsive Hodgkin lymphoma

Posted by on Jul 9, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This article reviewed current treatment options for patients with Hodgkin lymphoma (HL) that has come back (relapsed) or stopped responding to treatment (refractory). Some background Chemotherapy remains the standard first-line treatment for HL. One of the most commonly used regimens is ABVD (doxorubicin, bleomycin, vinblastine,...

Read More

Searching for patients with recurrent or non-responsive lymphoma to try this new treatment option

Posted by on Jun 29, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 1 study is evaluating the safety and effectiveness of a new T-cell therapy combined with nivolumab (Opdivo) for patients with lymphoma that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have side effects. This study is recruiting in Washington, D.C. and Salt...

Read More

Searching for patients with relapsed or unresponsive non-Hodgkin lymphoma to try a new cell therapy

Posted by on Jun 24, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This Phase 2 study is evaluating the safety and effectiveness of a new T-cell therapy for B-cell non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. The main outcomes to be measured will be the number of patients who experience side effects and overall response after treatment. This trial is recruiting...

Read More

Evaluating RBD chemotherapy for recurrent or non-responsive non-Hodgkin lymphoma

Posted by on Jun 21, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated how safe and effective RBD (rituximab, bendamustine, and dexamethasone) chemotherapy was for patients with B-cell non-Hodgkin lymphoma (NHL). This study concluded that this new regimen showed promising effectiveness for these patients. Some background Chemoimmunotherapy remains the standard first-line treatment...

Read More

Looking for older patients with acute myeloid leukemia to test a new treatment combination

Posted by on Jun 14, 2019 in Leukemia | 0 comments

In a nutshell This study is evaluating how well CPI-613 plus chemotherapy works in older patients with acute myeloid leukemia (AML) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This trial is taking place across the United...

Read More